For example, in our laboratory, transforming growth factor β 2 (TGFβ2) and homeobox D3 (HOXD3) hypermethylation has been discovered as potential biomarkers of prostate cancer progression through a genome-wide DMH screening [42, 43]. Here, HOXD3 is linked to prostate carcinoma.